Novartis to acquire UK-based ocular gene therapy company
Swiss pharmaceutical giant Novartis said Wednesday it was to acquire a UK-based biotech company developing gene therapies for eye diseases called Gyroscope Therapeutics.
Dec 22, 2021
0
2
Swiss pharmaceutical giant Novartis said Wednesday it was to acquire a UK-based biotech company developing gene therapies for eye diseases called Gyroscope Therapeutics.
Dec 22, 2021
0
2
(AP) -- Doctors were mostly hoping to prevent complications and relapses when they gave young women a medicine to keep their bones strong during breast cancer treatment. Seven years later, they found it did more than that: ...
Dec 9, 2011
0
0
The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration
Nov 16, 2011
0
0
NHS doctors should be allowed to prescribe a cheap, safe and effective drug for the degenerative eye disease, wet age related macular degeneration (AMD) - a leading cause of blindness among older patients, says an investigation ...
Apr 1, 2015
0
49
Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business, the company said in a statement Friday.
Jan 16, 2015
0
9
Two children who received Zolgensma, a gene therapy produced by Swiss drugmaker Novartis to treat spinal muscular atrophy, have died from liver failure, the company said Friday.
Aug 12, 2022
0
13
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination ...
Oct 20, 2013
0
0
When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like "breakthrough," "revolutionary" and "a watershed moment."
Aug 24, 2017
0
3
EU regulators have approved Novartis's new Piqray drug to treat advanced breast cancer, the Swiss pharma giant said Wednesday.
Jul 29, 2020
0
5
One hundred million treatments of Coartem Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic ...
Feb 22, 2012
0
0